's investigational cell therapy Revascor consists of 150 million allogeneic mesenchymal precursor cells (MPCs) and is being developed for injection into heart muscle of patients with moderate-advanced or end-stage chronic heart failure.
The ongoing, placebo-controlled double-blind Phase 3 trial of Mesoblast
's heart failure cellular medicine Revascor, comprising 150 million MPCs, is evaluating the immunotherapy for reduction of heart failure-related hospitalizations and terminal cardiac events in patients with advanced heart failure.
has previously received fast track designation from the FDA for remestemcel-L in SR- aGVHD and is eligible for priority review once the BLA filing is completed and accepted by the FDA.
"The safety and efficacy results of this study are very encouraging and suggest that Mesoblast
's cell therapy has the potential to fill the major unmet medical need of the biologic refractory RA population, where agents that provide consistent durable effects without the risk of opportunistic infections or malignancies are sorely needed," said Dr.
* The report provides brief overview of Mesoblast
Limited including business description, key information and facts, and its locations and subsidiaries
The Japanese patent underpins Mesoblast
's corporate strategy to protect intellectual property covering its lead clinical products, to safeguard its manufacturing processes and knowledge, and to extend the commercial reach of its proprietary technologies in the world's major markets for regenerative medicines.
The flexibility of Rave allows Mesoblast
to proactively adjust a trial s data validation plan and management processes, and also apply learnings to other studies in a timely fashion to improve trial quality and efficiency.
- Results generated from this Phase 2 trial may enable Mesoblast
to expand its therapeutic programs in Type 2 diabetes and metabolic diseases to address the large unmet medical needs of Type 2 diabetes patients with renal complications and the associated increase in cardiovascular morbidity and mortality.
The Australian company will initially receive $130 million from Cephalon for the therapy rights, with $30 million of it due upon approval of Mesoblast
Australian adult stem cell company Mesoblast
Limited today announced positive initial results of clinical adult stem cell trials for the treatment of heart disease.
Release date- 14082019 - Melbourne - Mesoblast
Limited (ASX: MSB; Nasdaq: MESO), global leader in cellular medicines for inflammatory diseases, today announced that it intends to provide its allogeneic cell therapy product candidate remestemcel-L for evaluation under an investigator-initiated Investigational New Drug (IND) submission as a potential treatment in children with steroid-refractory chronic graft-versus-host disease (GVHD).
NEW YORK, N.Y., March 26 -- Australian stem cell company Mesoblast
Limited (NASDAQ:MESO) and the International Center for Health Outcomes and Innovation Research (InCHOIR) at the Icahn School of Medicine at Mount Sinai have signed a Memorandum of Understanding (MOU) to conduct a confirmatory clinical trial using Mesoblast
's product candidate Revascor (MPC-150-IM) for reduction of gastrointestinal (GI) bleeding in end-stage heart failure patients implanted with a left ventricular assist device (LVAD).
announced that the FDA has agreed that Mesoblast
can submit on a rolling basis a Biologics License Application, or BLA, for its allogeneic cellular medicine remestemcel-L in children with steroid-refractory acute Graft Versus Host Disease, or SR-aGVHD.
[USPRwire, Fri Jan 23 2015] Global Markets Direct's, 'Mesoblast
Limited - Product Pipeline Review - 2014', provides an overview of the Mesoblast
Limited's pharmaceutical research and development focus.
US-based stem cell company Osiris Therapeutics (NasdaqGM :OSIR) reported on Wednesday the receipt of the next payment of USD15m in cash from Mesoblast
under the Purchase Agreement relating to the Prochymal business.